Fulvestrant Monotherapy After CDK4/6 Inhibitors in Metastatic Breast Cancer Patients: A Real-Life Experience.

Cancers (Basel) · 2024 · PMC11674525 · PMID 39766078

Europe PMC DOI

hedged sentence

0.6640

closest p · 13.3× alpha

0.6640

boldest claim

The sentences

did not reach statistical significancep = 0.664not close (p > 0.1)

The final results, presented at the American Society of Clinical Oncology (ASCO) 2023, indicated a median OS increase of 13.1 months in the abemaciclib arm; however, despite its clinical significance, this improvement did not reach statistical significance (HR 0.804; 95% CI, 0.6737–1.015; p = 0.664) [ 10 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.